Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2/Phase 3
REJOICE-Ovarian01
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- NCT06161025 ↗
- Recruiting
- Daiichi Sankyo
- Standard
We haven't built an HCP commentary report on REJOICE-Ovarian01 (R-DXd, topotecan and 2 more in Solid Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on REJOICE-Ovarian01 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| Podcasts | 8 | |
| YouTube | 6 | |
| X threads | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- Phase
- Phase 2/Phase 3
- Status
- Recruiting
- Conditions
- Solid Cancer
- Interventions
- R-DXd; Paclitaxel; Topotecan; PLD
- Arms
- Part A: R-DXd 4.8mg/kg Q3W · Experimental
- Part A: R-DXd 5.6 mg/kg Q3W · Experimental
- Part A: R-DXd 6.4 mg/kg Q3W · Experimental
- Part B: R-DXd RP3D Q3W · Experimental
- Part B: Investigator's Choice · Active comparator
- Enrollment
- 860 (estimated)
- Primary outcomes
- Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Assessment (Part A)
- Progression-free Survival (PFS) Based on BICR Assessment (Part B)
- Sponsor
- Daiichi Sankyo with Merck Sharp & Dohme LLC
- Start
- Feb 27, 2024
- Primary completion
- Feb 29, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06161025 · updated Oct 26, 2026